Hosted on MSN24d
Abcuro secures $200m as it eyes approval for rare muscle disease drug
US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
BMJ26d
Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
manchester.ac.uk Objectives Autoantibodies directed against cytosolic 5′-nucleotidase 1A have been identified in many patients with inclusion body myositis ... presence of dysphagia, comorbidities), ...
Physician's Weekly10d
Impact of Placebo on Muscle Strength and Function in Inclusion Body Myositis Trials
The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...
Yahoo Finance23d
Inclusion Body Myositis Pipeline Market Landscape Report 2025 Featuring Abcuro, Regeneron Pharmaceuticals, and Vandria
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into ...
BioWorld12d
New in vitro model of inclusion body myositis based on human iPSC-myotubes
Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...
BMJ26d
Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
UK Objectives The diagnosis of inclusion body myositis (IBM) can be challenging as it can be difficult to clinically distinguish from other forms of myositis, particularly polymyositis (PM). Recent ...